Skip to main content
SpringerLink
Log in

The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition

  • Chapter
Targeted Interference with Signal Transduction Events

Part of the book series: Resent Results in Cancer Research ((RECENTCANCER,volume 172))

Abstract

Human cancer expression profiling studies highlight the important variability in gene expression patterns and signaling pathways activated within tumors of a homogenous pathological group. These observations support the need for marker and molecular signature identification to adapt appropriate treatments to the patient. Increasing evidence indicates that the mammalian target of rapamycin [mTOR; also named rapamycin-associated protein (FRAP) or rapamycin and FKBP12 target (RAFT)] signaling pathway is hyperactive in a number of cancers, suggesting that this pathway may represent an attractive target for cancer therapy. mTOR is a highly conserved, 290-kDa serine-threonine protein kinase that belongs to the phosphoinositide kinase-related kinase (PIKK) family comprising also ataxia-telangiectasia (ATM), ATM and Rad3-related protein kinase (ATR) and DNA-dependent protein kinase (DNA-PK) (Abraham 2004).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abraham RT (2004) PI 3-kinase related kinases: ‘big’ players in stress-induced signaling pathways. DNA Repair (Amst) 3:883–887

    Article  PubMed  CAS  Google Scholar 

  • Albert JM, Kim KW, Cao C, Lu B (2006) Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 5:1183–1189

    Article  PubMed  CAS  Google Scholar 

  • Ali SM, Sabatini DM (2005) Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J Biol Chem 280:19445–19448

    Article  PubMed  CAS  Google Scholar 

  • Aoki M, Blazek E, Vogt PK (2001) A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3K and Akt. Proc Natl Acad Sci USA 98:136–141

    Article  PubMed  CAS  Google Scholar 

  • Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, Polunovsky VA (2004) Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5:553–563

    Article  PubMed  CAS  Google Scholar 

  • Awada A, Cardoso F, Fontaine C, Dirix L, De Grve J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Ressayre-Djaffer C, Piccart M (2004) A phase Ib study of the mTOR inhibitor RAD001(everolimus) in combination with letrozole (Femara), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or progressing on letrozole. Breast Cancer Res Treat 88(suppl 1):S234

    Google Scholar 

  • Awada A, Cardoso F, Fontaine C, Dirix L, De Grève J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M (Manuscript in preparation) The mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer. Results of a phase 1 study with pharmacokinetics.

    Google Scholar 

  • Beuvink I, O’Reilly T, Zumstein-Mecker S, Zilbermann F, Sedrani R, Kozma SC, Thomas G, Lane HA (2001) Antitumor activity of RAD001, an orally active rapamycin derivative. Proc Am Assoc Cancer Res 42:366

    Google Scholar 

  • Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O’Reilly T, Natt F, Hall J, Lane HA, Thomas G (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120:747–759

    Article  PubMed  CAS  Google Scholar 

  • Boulay A, Hattenberger M, Maira SM, Thomas G, Merlo A, O’Reilly T, Lane HA (2003) Phospho-Akt levels as potential biomarker of in vitro sensitivity of tumor cell lines to the mTOR pathway inhibitor RAD001. Proc AACR-NCI-EORTC Abstract 1096

    Google Scholar 

  • Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O’Reilly T, Stolz B, Marti A, Thomas G, Lane HA (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252–261

    Article  PubMed  CAS  Google Scholar 

  • Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O’Reilly T, Evans DB, Chen S, Lane HA (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11:5319–5328

    Article  PubMed  CAS  Google Scholar 

  • Brugarolas J, Vazquez F, Reddy A, Sellers WR, Kaelin WG (2003) TCS2 regulates VEGF through mTOR-dependent and-independent pathways. Cancer Cell 4:147–158

    Article  PubMed  CAS  Google Scholar 

  • Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr. (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18:2893–2904

    Article  PubMed  CAS  Google Scholar 

  • Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95:1432–1437

    Article  PubMed  CAS  Google Scholar 

  • Carling D (2004) The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 29:18–24

    Article  PubMed  CAS  Google Scholar 

  • Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M, Fiorentino R, Varricchio L, Barone MV, Auricchio F (2001) PI3-kinase in concert with Src promotes the S-phase entry of oestradiolstimulated MCF-7 cells. EMBO J 20:6050–6059

    Article  PubMed  CAS  Google Scholar 

  • Castro AF, Rebhun JF, Clark GJ, Quilliam LA (2003) Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin-and farnesylation-dependent manner. J Biol Chem 278:32493–32496

    Article  PubMed  CAS  Google Scholar 

  • Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91:1420–1424

    Article  PubMed  CAS  Google Scholar 

  • Cheng SW, Fryer LG, Carling D, Shepherd PR (2004) Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem 279:15719–15722

    Article  PubMed  CAS  Google Scholar 

  • Chiang GG, Abraham RT (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280:25485–25490

    Article  PubMed  CAS  Google Scholar 

  • Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS (2003) Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746

    PubMed  CAS  Google Scholar 

  • Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A, Lopez-Rios F, Sanchez-Cespedes M (2006) Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 12:710–717

    Article  PubMed  CAS  Google Scholar 

  • Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL (2004) Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18:1533–1538

    Article  PubMed  CAS  Google Scholar 

  • Corradetti MN, Inoki K, Guan KL (2005) The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem 280:9769–9772

    Article  PubMed  CAS  Google Scholar 

  • Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcome in breast-cancer prevention trials. Lancet 361:296–300

    Article  PubMed  CAS  Google Scholar 

  • Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH (2005) Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 65:2755–2760

    Article  PubMed  CAS  Google Scholar 

  • De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189–3199

    Article  PubMed  CAS  Google Scholar 

  • deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 10:8059–8067

    Article  PubMed  CAS  Google Scholar 

  • Dengler J, von Bubnoff N, Decker T, Peschel C, Duyster J (2005) Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. Leukemia 19:1835–1838

    Article  PubMed  CAS  Google Scholar 

  • Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G (2001) Mammalian TOR: a homeostatic ATP sensor. Science 294:1102–1105

    Article  PubMed  CAS  Google Scholar 

  • Dong J, Pan D (2004) Tsc2 is not a critical target of Akt during normal Drosophila development. Genes Dev 18:2479–2484

    Article  PubMed  CAS  Google Scholar 

  • Dutcher JP (2004) Mammalian target of rapamycin (mTOR) Inhibitors. Curr Oncol Rep 6:111–115

    Article  PubMed  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687–1717

    Article  CAS  Google Scholar 

  • Edinger AL, Thompson CB (2002) Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13:2276–2288

    Article  PubMed  CAS  Google Scholar 

  • Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT (2003) Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 63:8451–8460

    PubMed  CAS  Google Scholar 

  • Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN (2002) Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62:7291–7297

    PubMed  CAS  Google Scholar 

  • Feng Z, Zhang H, Levine AJ, Jin S (2005) The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 102:8204–8209

    Article  PubMed  CAS  Google Scholar 

  • Fingar DC, Salama S, Tsou C, Harlow E, Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16:1472–1487

    Article  PubMed  CAS  Google Scholar 

  • Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24:200–216

    Article  PubMed  CAS  Google Scholar 

  • Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex Ann Neurol 59:490–498

    Article  PubMed  CAS  Google Scholar 

  • Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294–5304

    Article  PubMed  CAS  Google Scholar 

  • Gangloff YG, Mueller M, Dann SG, Svoboda P, Sticker M, Spetz JF, Um SH, Brown EJ, Cereghini S, Thomas G, Kozma SC (2004) Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 24:9508–9516

    Article  PubMed  CAS  Google Scholar 

  • Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Ru B, Pan D (2002) Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4:699–704

    Article  PubMed  CAS  Google Scholar 

  • Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11:1457–1466

    Article  PubMed  CAS  Google Scholar 

  • Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK (2004) AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279:2737–2746

    Article  PubMed  CAS  Google Scholar 

  • Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N (1999) Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13:1422–1437

    PubMed  CAS  Google Scholar 

  • Gingras AC, Raught B, Sonenberg N (2001) Regulation of translation initiation by FRAP/mTOR. Genes Dev 15:807–826

    Article  PubMed  CAS  Google Scholar 

  • Goss PE (2003a) Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol 26:S27–33

    Article  PubMed  Google Scholar 

  • Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003b) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802

    Article  PubMed  CAS  Google Scholar 

  • Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4:101–112

    PubMed  CAS  Google Scholar 

  • Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62:6141–6145

    PubMed  CAS  Google Scholar 

  • Guarneri V, Conte PF (2004) The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 31Suppl 1:S149–S161

    Article  PubMed  Google Scholar 

  • Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135

    Article  PubMed  CAS  Google Scholar 

  • Guertin DA, Sabatini DM (2005) An expanding role for mTOR in cancer. Trends Mol Med 11:353–361

    Article  PubMed  CAS  Google Scholar 

  • Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N (2005) Akt Activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK Activity. J Biol Chem 280:32081–32089

    Article  PubMed  CAS  Google Scholar 

  • Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J (1998) Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 273:14484–14494

    Article  PubMed  CAS  Google Scholar 

  • Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177–189

    Article  PubMed  CAS  Google Scholar 

  • Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166:213–223

    Article  PubMed  CAS  Google Scholar 

  • Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2:28

    Article  PubMed  Google Scholar 

  • Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926–1945

    Article  PubMed  CAS  Google Scholar 

  • Hay N (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8:179–183

    Article  PubMed  CAS  Google Scholar 

  • Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2006) Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat Rev Drug Discovery 4:988–1004

    Google Scholar 

  • Hidalgo M, Rowinsky EK (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19:6680–6686

    Article  PubMed  CAS  Google Scholar 

  • Holz MK, Blenis J (2005) Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 280:26089–26093

    Article  PubMed  CAS  Google Scholar 

  • Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, Lavoinne A, Hue L, Proud C, Rider M (2002) Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12:1419–1423

    Article  PubMed  CAS  Google Scholar 

  • Huang S, Houghton PJ (2003) Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3:371–377

    Article  PubMed  CAS  Google Scholar 

  • Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354

    Article  PubMed  CAS  Google Scholar 

  • Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648–657

    Article  PubMed  CAS  Google Scholar 

  • Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577–590

    Article  PubMed  CAS  Google Scholar 

  • Inoki K, Corradetti MN, Guan KL (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37:19–24

    Article  PubMed  CAS  Google Scholar 

  • Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122–1128

    Article  PubMed  CAS  Google Scholar 

  • Janicke F (2004) Are all aromatase inhibitors the same? A review of the current evidence. Breast 13Suppl 1: S10–S18

    Article  PubMed  Google Scholar 

  • Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G (1997) Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 16:3693–3704

    Article  PubMed  CAS  Google Scholar 

  • Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102:8573–8578

    Article  PubMed  CAS  Google Scholar 

  • Johnston SR (2005) Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 11:889s–899s

    PubMed  CAS  Google Scholar 

  • Kanazawa T, Taneike I, Akaishi R, Yoshizawa F, Furuya N, Fujimura S, Kadowaki M (2004) Amino acids and insulin control autophagic proteolysis through different signaling pathways in relation to mTOR in isolated rat hepatocytes. J Biol Chem 279:8452–8459

    Article  PubMed  CAS  Google Scholar 

  • Kenerson HL, Aicher LD, True LD, Yeung RS (2002) Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62:5645–5650

    PubMed  CAS  Google Scholar 

  • Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163–175

    Article  PubMed  CAS  Google Scholar 

  • Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM (2003) GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11:895–904

    Article  PubMed  CAS  Google Scholar 

  • Kimura N, Tokunaga C, Dalal S, Richardson C, Yoshino K, Hara K, Kemp BE, Witters LA, Mimura O, Yonezawa K (2003) A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 8:65–79

    Article  PubMed  CAS  Google Scholar 

  • Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726–734

    Article  PubMed  CAS  Google Scholar 

  • Krause U, Bertrand L, Hue L (2002) Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. Eur J Biochem 269:3751–3759

    Article  PubMed  CAS  Google Scholar 

  • Lane HA, Schnell A, Theuer T, O’Reilly T, Wood J (2002) Antiangiogenic activity of RAD001, an orally active anticancer agent. Proc Am Assoc Cancer Res 43:922

    Google Scholar 

  • Lane HA, Boulay A, Hattenberger M, Maira SM, Thomas G, Merlo A, O’Reilly T (2003a) The orally active rapamycin derivative RAD001 has potential as an antitumor agent with a broad antiproliferative activity: PTEN as a molecular determinant of response. Proc Am Assoc Cancer Res 44:314

    Google Scholar 

  • Lane HA, Tanaka C, Kovarik J, O’Reilly T, Zumstein-Mecker S, McMahon LM, Cohen P, O’Donnell A, Judson I, Raymond E (2003b) Preclinical and clinical pharmacokinetic/pharmacodynamic (PK/PD) modeling to help define an optimal biological dose for the oral mTOR inhibitor, RAD001, in oncology. Proc Am Soc Clin Oncol 22:237

    Google Scholar 

  • Li Y, Inoki K, Guan KL (2004) Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol 24:7965–7975

    Article  PubMed  CAS  Google Scholar 

  • Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC (2006) Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 21:521–531

    Article  PubMed  CAS  Google Scholar 

  • Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10:457–468

    Article  PubMed  CAS  Google Scholar 

  • Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J (2005a) Rheb binds and regulates the mTOR kinase. Curr Biol 15:702–713

    Article  PubMed  CAS  Google Scholar 

  • Long X, Ortiz-Vega S, Lin Y, Avruch J (2005b) Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 280:23433–23436

    Article  PubMed  CAS  Google Scholar 

  • Lum JJ, DeBerardinis RJ, Thompson CB (2005) Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 6:439–448

    Article  PubMed  CAS  Google Scholar 

  • Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005a) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121:179–193

    Article  PubMed  CAS  Google Scholar 

  • Ma L, Teruya-Feldstein J, Behrendt N, Chen Z, Noda T, Hino O, Cordon-Cardo C, Pandolfi PP (2005b) Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev 19:1779–1786

    Article  PubMed  CAS  Google Scholar 

  • Mach KE, Furge KA, Albright CF (2000) Loss of Rhb1, a Rheb-related GTPase in fission yeast, causes growth arrest with a terminal phenotype similar to that caused by nitrogen starvation. Genetics 155:611–622

    PubMed  CAS  Google Scholar 

  • Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594–601

    Article  PubMed  CAS  Google Scholar 

  • Manning BD, Cantley LC (2003) Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 28:573–576

    Article  PubMed  CAS  Google Scholar 

  • Manning BD (2004) Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167:399–403

    Article  PubMed  CAS  Google Scholar 

  • Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19:1773–1778

    Article  PubMed  CAS  Google Scholar 

  • Marx SO, Jayaraman T, Go LO, Marks AR (1995) Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76:412–417

    PubMed  CAS  Google Scholar 

  • Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG (2004) Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 101:3130–3135

    Article  PubMed  CAS  Google Scholar 

  • Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F (2004) Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10:7031–7042

    Article  PubMed  CAS  Google Scholar 

  • Mordier S, Deval C, Bechet D, Tassa A, Ferrara M (2000) Leucine limitation induces autophagy and activation of lysosome-dependent proteolysis in C2C12 myotubes through a mammalian target of rapamycin-independent signaling pathway. J Biol Chem 275:29900–29906

    Article  PubMed  CAS  Google Scholar 

  • Mothe-Satney I, Brunn GJ, McMahon LP, Capaldo CT, Abraham RT, Lawrence JC Jr (2000) Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies. J Biol Chem 275:33836–33843

    Article  PubMed  CAS  Google Scholar 

  • Murakami M, Ichisaka T, Maeda M, Oshiro N, Hara K, Edenhofer F, Kiyama H, Yonezawa K, Yamanaka S (2004) mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 24:6710–6718

    Article  PubMed  CAS  Google Scholar 

  • Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR (1999) Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 344 Pt 2:427–431

    Article  PubMed  CAS  Google Scholar 

  • Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314–10319

    Article  PubMed  CAS  Google Scholar 

  • Ng Grace, Huang J (2005) The significance of autophagy in cancer. Mol Carcinogenesis 43:183–187

    Article  CAS  Google Scholar 

  • Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY, Gulati P, Byfield MP, Backer JM, Natt F, Bos JL, Zwartkruis FJ, Thomas G (2005) Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA

    Google Scholar 

  • Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013–1023

    Article  PubMed  CAS  Google Scholar 

  • O’Donnell A, Faivre S, Judson I, Delbado C, Brock C, Lane HA, Shand N, Hazell K, Armand JP, Raymond E (2003) A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumors. Proc Am Soc Clin Oncol 22:200

    Google Scholar 

  • Ohanna M, Sobering AK, Lapointe T, Lorenzo L, Praud C, Petroulakis E, Sonenberg N, Kelly PA, Sotiropoulos A, Pende M (2005) Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat Cell Biol 7:286–294

    Article  PubMed  CAS  Google Scholar 

  • O’Reilly T, Vaxelaire J, Muller M (2002) In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Asso Cancer Res 43:71

    Google Scholar 

  • O’Reilly T, Muller M, Hattenberger M, Vaxelaire J, Lane HA (2003) Antitumor activity of RAD001 in combination with cytotoxic agents. Proc Am Assoc Cancer Res 44:136

    Google Scholar 

  • O’Reilly T, Wood J, Littlewood-Ewans A, Boulay A, Schnell C, Sini P, Maira MS, Martiny-Baron G, Lane HA (2005) Differential anti-vascular effects of mTOR or VEGFR pathway inhibition: A rational basis for combining RAD001 and PTK787/ZK222584. Proc Am Assoc Cancer Res 46:715

    Google Scholar 

  • O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane HA, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500–1508

    Article  PubMed  CAS  Google Scholar 

  • Pang H, Faber LE (2001) Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells. Breast Cancer Res Treat 70:21–26

    Article  PubMed  CAS  Google Scholar 

  • Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24:3112–3124

    Article  PubMed  CAS  Google Scholar 

  • Peng T, Golub TR, Sabatini DM (2002) The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 22:5575–5584

    Article  PubMed  CAS  Google Scholar 

  • Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG, Hay N (2003) Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17:1352–1365

    Article  PubMed  CAS  Google Scholar 

  • Perez-Tenorio G, Stal O (2002) Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540–545

    Article  PubMed  CAS  Google Scholar 

  • Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc Natl Acad Sci USA 98:10320–10325

    Article  PubMed  CAS  Google Scholar 

  • Proud CG (2004) The multifaceted role of mTOR in cellular stress responses. DNA Repair (Amst) 3:927–934

    Article  PubMed  CAS  Google Scholar 

  • Reiling JH, Hafen E (2004) The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev 18:2879–2892

    Article  PubMed  CAS  Google Scholar 

  • Roccio M, Bos JL, Zwartkruis FJ (2005) Regulation of the small GTPase Rheb by amino acids. Oncogene 25:657–664

    Article  CAS  Google Scholar 

  • Rojo F, Iglesias C, Tabernerro J, Jimenez J, Rodriguez S, Bellmunt J, Ramon S, Baselga J (2004) Molecular markers of the mTOR pathway activation in human tumors: a baseline analysis. Proc Am Soc Clin Oncol 22:14S

    Google Scholar 

  • Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ben Ayed F, Burdette-Radoux S, Chaudri-Ross HA, Lang R (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318–2327

    Article  PubMed  CAS  Google Scholar 

  • Rousseau D, Gingras AC, Pause A, Sonenberg N (1996) The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 13:2415–2420

    PubMed  CAS  Google Scholar 

  • Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101:13489–13494

    Article  PubMed  CAS  Google Scholar 

  • Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, Dor Y, Zisman P, Meyuhas O (2005) Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 19:2199–2211

    Article  PubMed  CAS  Google Scholar 

  • Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Onc 18:77–82

    Article  CAS  Google Scholar 

  • Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296–1302

    Article  PubMed  CAS  Google Scholar 

  • Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101

    Article  PubMed  CAS  Google Scholar 

  • Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159–168

    Article  PubMed  CAS  Google Scholar 

  • Schalm SS, Blenis J (2002) Identification of a conserved motif required for mTOR signaling. Curr Biol 12:632–639

    Article  PubMed  CAS  Google Scholar 

  • Schalm SS, Fingar DC, Sabatini DM, Blenis J (2003) TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 13:797–806

    Article  PubMed  CAS  Google Scholar 

  • Scheper GC, Proud CG (2002) Does phosphorylation of the cap-dependent protein eIF4E play a role in translation initiation. Eur J Biochem 269:5350–5359

    Article  PubMed  CAS  Google Scholar 

  • Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103:253–262

    Article  PubMed  CAS  Google Scholar 

  • Schwarzer R, Tondera D, Arnold W, Giese K, Klippel A, Kaufmann J (2005) REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene 24:1138–1149

    Article  PubMed  CAS  Google Scholar 

  • Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC, Jr. (1998) Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci USA 95:7772–7777

    Article  PubMed  CAS  Google Scholar 

  • Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT (2000) A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60:3504–3513

    PubMed  CAS  Google Scholar 

  • Shah OJ, Wang Z, Hunter T (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14:1650–1656

    Article  PubMed  CAS  Google Scholar 

  • Shamji AF, Nghiem P, Schreiber SL (2003) Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell 12:271–280

    Article  PubMed  CAS  Google Scholar 

  • Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91–99

    Article  PubMed  CAS  Google Scholar 

  • Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB (1995) Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 55:1982–1988

    PubMed  CAS  Google Scholar 

  • Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, Lichtenstein A (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62:5027–5034

    PubMed  CAS  Google Scholar 

  • Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC (1998) Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 17:6649–6659

    Article  PubMed  CAS  Google Scholar 

  • Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, Lu B (2005) Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24:5414–5422

    Article  PubMed  CAS  Google Scholar 

  • Smith EM, Finn SG, Tee AR, Browne GJ, Proud CG (2005) The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J Biol Chem 280:18717–18727

    Article  PubMed  CAS  Google Scholar 

  • Smith IE (2004) Aromatase inhibitors in early breast cancer therapy. Semin Oncol 31:9–14

    Article  PubMed  CAS  Google Scholar 

  • Sofer A, Lei K, Johannessen CM, Ellisen LW (2005) Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol 25:5834–5845

    Article  PubMed  CAS  Google Scholar 

  • Stocker H, Radimerski T, Schindelholz B, Wittwer F, Belawat P, Daram P, Breuer S, Thomas G, Hafen E (2003) Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol 5:559–565

    Article  PubMed  CAS  Google Scholar 

  • Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65:7052–7058

    Article  PubMed  CAS  Google Scholar 

  • Tabernero J, Rojo F, Burris E, Casado E, Macarulla T, Jones S, Dimitrijevic S, Hazell K, Shand N, Baselga J (2005) A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol Abstract 3007

    Google Scholar 

  • Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S (2005) Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65:3336–3346

    PubMed  CAS  Google Scholar 

  • Tang H, Hornstein E, Stolovich M, Levy G, Livingstone M, Templeton D, Avruch J, Meyuhas O (2001) Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol Cell Biol 21:8671–8683

    Article  PubMed  CAS  Google Scholar 

  • Tee AR, Anjum R, Blenis J (2003a) Inactivation of the tuberous sclerosis complex-1 and-2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and-independent phosphorylation of tuberin. J Biol Chem 278:37288–37296

    Article  PubMed  CAS  Google Scholar 

  • Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J (2003b) Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13:1259–1268

    Article  PubMed  CAS  Google Scholar 

  • Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122–127

    Article  PubMed  CAS  Google Scholar 

  • Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A, Breast International Group (BIG) 1–98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757

    Article  PubMed  Google Scholar 

  • Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G (2004) Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200–205

    Article  PubMed  CAS  Google Scholar 

  • Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G (2005) Breast cancer. Lancet 365:1727–41

    Article  PubMed  Google Scholar 

  • Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525–537

    Article  PubMed  CAS  Google Scholar 

  • Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501

    Article  PubMed  CAS  Google Scholar 

  • Weiss RH (2003) p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 4:425–429

    Article  PubMed  CAS  Google Scholar 

  • Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332–337

    Article  PubMed  CAS  Google Scholar 

  • Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13:2004–2008

    Article  PubMed  CAS  Google Scholar 

  • Wu L, Birle DC, Tannock IF (2005) Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65:2825–2831

    Article  PubMed  CAS  Google Scholar 

  • Wullschleger S, Loewith R, Oppliger W, Hall MN (2005) Molecular organization of target of rapamycin complex 2. J Biol Chem 280:30697–30704

    Article  PubMed  CAS  Google Scholar 

  • Xu G, Zhang W, Bertram P, Zheng XF, McLeod H (2004) Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24:893–900

    PubMed  CAS  Google Scholar 

  • Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, Gibbons JJ (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249–258

    Article  PubMed  Google Scholar 

  • Yue W, Wang JP, Conaway MR, Li Y, Santen RJ (2003) Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol 86:265–274

    Article  PubMed  CAS  Google Scholar 

  • Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ (2003a) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112:1223–1233

    Article  PubMed  CAS  Google Scholar 

  • Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D (2003b) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5:578–581

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich Miescher Institute for Biomedical Research, Maulbeerstr. 66, 4059, Basel, Switzerland

    Anne Boulay PhD (Post-doctoral Fellow)

  2. Novartis Pharma AG, 4002, Basel, Switzerland

    Heidi A. Lane PhD (Unit Head, Director)

Authors
  1. Anne Boulay PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heidi A. Lane PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Georg-Speyer-Haus, Institute for Biomedical Research, Paul-Ehrlich-Str. 42-44, 60596, Frankfurt am Main, Germany

    Bernd Groner (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Boulay, A., Lane, H.A. (2007). The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition. In: Groner, B. (eds) Targeted Interference with Signal Transduction Events. Resent Results in Cancer Research, vol 172. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-31209-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-31209-3_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31208-6

  • Online ISBN: 978-3-540-31209-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation